|
Bahrain Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Bahrain Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Bahrain .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Bahraini pharmaceutical and healthcare industry.
Competitive intelligence, Bahraini pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Bahraini market.
The Bahrain Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Bahrain Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Bahraini pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Bahrain to test other views – a key input for successful budgeting and strategic business planning in the Bahraini pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Bahraini Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Bahrain .
- Exploit The Latest Competitive Bahraini Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Bahrain .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Bahrain Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Bahrain Pharmaceuticals And Healthcare Industry SWOT |
| Bahrain Political SWOT |
| Bahrain Economic SWOT |
| Bahrain Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Middle East And Africa Pharmaceutical Business Environment Ratings for Q209 |
| Limits of Potential Returns |
| Risks to Realisation of Returns |
Chapter - Bahrain – Market Summary |
| Regulatory Regime |
| Recent Regulatory Developments |
| GCC Healthcare Collaboration |
| Intellectual Property Developments |
| Pricing and Reimbursement Regime |
| Regional Price Harmonisation |
| Free Trade Agreement with the US |
| Other Free Trade Agreements |
Chapter - Industry Developments |
| Epidemiology |
| Table: Leading Causes Of Death In Bahrain, 2002 |
| HIV/AIDS |
| Healthcare Sector |
| Primary, Secondary and Tertiary Healthcare |
| Health Insurance |
| Table: National Health Insurance Scheme Breakdown |
| Strategic Healthcare Goals |
| Healthcare Sector Investment |
| Features Of Dilmunia Health Island |
| Pharmaceutical Sector |
| Pharmaceutical Retail |
| Research and Development |
| International Collaboration |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Bahrain - Drug Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: Bahrain - Health Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Macroeconomic |
| Table: Bahrain - Economic Activity |
| Prescription Market Forecast |
| Table: Bahrain – Prescription Market Indicators, Historical Data and Forecasts (BHDmn unless otherwise indicated) |
| Patented Market Forecast |
| Table: Bahrain - Prescription Drug Market Indicators, Historical Data and Forecasts |
| Generics Drug Market Forecast |
| Table: Bahrain - Generics Drug Market Indicators, Historical Data and Forecasts |
| OTC Market Forecast |
| Table: Bahrain - OTC Market Indicators, Historical Data and Forecasts (BHDmn unless otherwise stated) |
| Pharmaceutical Trade Forecast |
| Table: Bahrain - Pharmaceutical Trade Balance Indicators, Historical Data and Forecasts (US$mn) |
| Medical Devices |
| Table: Bahrain - Medical Device Market Indicators, Historical Data and Forecasts (US$mn unless otherwise stated) |
| Other Healthcare Data Forecasts |
| Table: Bahrain - Other Health Indicators, Historical Data and Forecasts |
| Key Risks to BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Monitor |
| Multinational Companies |
| Novartis |
| Johnson & Johnson |
| Merck & Co |
| Pfizer |
| GlaxoSmithKline |
| GlaxoSmithKline |
| Indigenous Companies |
| Bahrain Industrial Pharmaceutical Co (Bidapharm) |
| Al-Jishi Corporation |
| Behzad Medical Establishment |
| Yousuf Mahmood Husain Company |
Chapter - Country Snapshot: Bahrain Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education and Healthcare |
| Table: Education |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market and Spending Power |
| Table: Employment Indicators |
| Table: Consumer Expenditure, 1999-2004 (US$) |
| Table: Average Annual Wages |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Bahrain Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In BMI’s Q209 Business Environment Rating for the 17 countries of the MEA region, Bahrain improved its position to fourth, from equal sixth. While the country’s overall score is negatively impacted by the small population, the low-risk economic and political climates and strong pharmaceutical-specific regulatory framework represent major positives for foreign drugmakers, especially given the preference for patented and branded prescription drugs, a relatively generous reimbursement system and the unchallenging distribution network. The population is also growing relatively quickly, which should help to boost future returns, Overall, we expect total drug market spending to increase from US$73.2mn in 2008 to US$97.6mn by 2013, implying a steady compound annual growth rate (CAGR) of just over 5.9%.
The demand for healthcare services is expected to increase considerably, especially as chronic and longterm diseases have come to represent most of the mortality and morbidity burden. For example, according to a February 2009 TradeArabia article, the number of newborn children with type I (insulin-dependent) diabetes rose almost tripled between 1993 and 2008. Similarly, around 26% of Bahraini population presently suffers from hypertension, while asthma has also emerged as a pressing health concern due to worsening air quality.
On a positive note, in March 2009 the Bahraini health minister announced that the number of patients presenting with sickle cell anaemia and thalassemia fell as a result of the government's pre-marriage screening programmes and improved treatment of sufferers. The long-term health policy instilled by the state not only includes designated hospital units for sickle cell anaemic children, but also plans to finance additional facilities to treat adults. BMI believes that Bahrain's successful strategy for preventing congenital diseases will be attractive to multinational firms involved in genetic sequencing and anaemic disease management.
On an economic front, the news is similarly encouraging. While there are substantial macroeconomic risks in 2009 – but assuming an oil price bounce in the second half of the year – Bahrain should continue to record positive real growth rates. Nevertheless, we have revised down our forecasts for Bahraini growth to 3.5% in 2009 from our previous projection of 4.3%. The changes were made on the premise that the services-oriented economies are more exposed to global consumer demand and liquidity shortages, and will therefore be affected to a larger degree. Against this backdrop, we are forecasting consumer spending growth of 3.0% for 2009 and 2010, rising to 4.0% in 2011-2012 and then 5.0% in 2013. This should also work towards supporting the development of the over-the-counter (OTC) medicines market, from a currently low base of US$3.7mn. OTCs will also be boosted by the recent Gulf Cooperation Council (GCC)-wide proposals to introduce harmonised traditional and alternative medicines legislation, put forward in response to the increase in the use of herbal treatments.
|
Bahrain Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |